Synopsis

Source of validity: Scientific
Rating (out of 5): 2

Enterococcus, particularly Enterococcus faecium and Enterococcus faecalis, has been studied for its potential probiotic properties in the management of Inflammatory Bowel Disorders (IBD), such as ulcerative colitis and Crohn’s disease. The rationale for its use is based on the ability of certain Enterococcus strains to modulate the gut microbiota, enhance mucosal barrier function, and exert immunomodulatory effects. Enterococcus is included in some multi-strain probiotic formulations (e.g., VSL#3, which contains Enterococcus faecium alongside other bacteria) that have demonstrated some benefit in clinical studies, especially for maintaining remission in ulcerative colitis and preventing pouchitis.

However, the scientific evidence supporting Enterococcus as a monotherapy for IBD is limited. Most positive results are from studies using multi-strain probiotics, making it difficult to attribute the benefit specifically to Enterococcus. Furthermore, safety concerns exist, as Enterococcus species can be opportunistic pathogens, especially in immunocompromised individuals. Systematic reviews and meta-analyses generally conclude that while some probiotics may help in IBD, the evidence for Enterococcus alone is weak and inconsistent.

In summary, the use of Enterococcus for IBD is supported by some scientific investigation, but the evidence is limited (rated 2/5), mostly indirect, and caution is warranted due to potential safety risks.

More about Enterococcus
More about Inflammatory Bowel Disorders

Other ingredients used for Inflammatory Bowel Disorders

Other health conditions supported by Enterococcus

Products containing Enterococcus